Demographics, Changes in Treatment Patterns, and Outcomes of Bone and Soft Tissue Sarcomas in Korea-A Sarcoma-Specific, Institutional Registry-Based Analysis

被引:3
|
作者
Jeong, Hyehyun [1 ]
Im, Hyeon-Su [1 ,2 ]
Kim, Wanlim [3 ]
Lee, Jong-Seok [3 ]
Song, Si Yeol [4 ]
Song, Joon Seon [5 ]
Cho, Kyung-Ja [5 ]
Chung, Hye Won [6 ]
Lee, Min Hee [6 ]
Kim, Jeong Eun [1 ]
Ahn, Jin-Hee [1 ]
机构
[1] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, 88 Olymp Ro 43 Gil, Seoul, South Korea
[2] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea
[3] Univ Ulsan, Asan Med Ctr, Dept Orthoped Surg, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Asan Med Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea
[6] Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea
来源
关键词
bone sarcoma; soft tissue sarcoma; sarcoma-specific registry; real-world evidence; ADJUVANT CHEMOTHERAPY; DOXORUBICIN; SURVIVAL;
D O I
10.2147/CMAR.S337606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Because of the heterogeneity of sarcomas, establishing a well-collected, sarcoma specific database is important for sarcoma research. We analyzed the first histology-based, sarcoma-specific institutional registry in Korea, which collected 28 years of patient data according to a predefined data format. Patients and Methods: Adult bone and soft tissue sarcoma patients who were treated from June 1989 to January 2017 were identified and analyzed, based on the ICD-O-3 codes. Results: Among the 3420 patients included, soft tissue and bone sarcomas comprised 77.8% (n = 2661) and 22.2% (n = 759), respectively. Median age at diagnosis was 50 (range, 16-98) in soft tissue sarcomas and 37 (range, 16-85) in bone sarcomas. Males and females comprised 45.5% and 54.5% of soft tissue sarcomas and 52.7% and 47.3% of bone sarcomas, respectively. Among the 3407 patients with treatment data available, 90.5% of the patients with soft tissue sarcomas and 80.8% of the patients with bone sarcomas received surgery first, of which 57.8% and 71.7% did not receive any subsequent treatment, respectively. Overall, the proportion of patients who received surgery alone decreased from 85.7% to 60.5% from the pre-2000 period to the 2010-2017 period. However, the use of adjuvant chemotherapy increased in patients with soft tissue sarcomas (from 8.0% to 17.2% in the same period), and the use of perioperative radiotherapy also increased in both groups (from 1.4% to 22.7% in soft tissue sarcomas, and 0% to 14.5% in bone sarcomas in the same period). In both soft tissue and bone sarcomas, old age (>= 65 years) and diagnosis in the early study period were associated with poorer survival. Conclusion: We presented a comprehensive summary of our sarcoma registry, including the demographics, changes in treatment patterns, and survival outcomes. This study will provide a framework for future studies.
引用
收藏
页码:8795 / 8802
页数:8
相关论文
共 8 条
  • [1] Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019
    Ogura, Koichi
    Morizane, Chigusa
    Satake, Tomoyuki
    Iwata, Shintaro
    Toda, Yu
    Muramatsu, Shudai
    Takemori, Toshiyuki
    Kondo, Hiroya
    Kobayashi, Eisuke
    Katoh, Yoko
    Higashi, Takahiro
    Kawai, Akira
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (11) : 1150 - 1157
  • [2] Subtype-Specific Patterns of Tumor Purity and Mutation Load Suggest Treatment Implications A Cross-Sectional Analysis of 7494 Soft Tissue and Bone Sarcomas (MSK Cohort)
    Schneider, Daniel
    Brown, Ethan D. L.
    Gluski, Jacob
    Mishra, Akash
    Shah, Harshal A.
    Sciubba, Daniel M.
    Lo, Sheng-Fu Larry
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 185 - 192
  • [3] Multimodality treatment of head-and-neck soft-tissue sarcomas and short-term outcomes: Analysis from sarcoma medical oncology clinic
    Vanidassane, Ilavarasi
    Sharma, Aparna
    Aggarwal, Aditi
    Gunasekar, Sudhakar
    Barwad, Adarsh
    Dhamija, Ekta
    Pandey, Rambha
    Deo, Suryanarayana
    Garg, Rakesh
    Rastogi, Sameer
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (01) : 69 - 71
  • [4] Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas
    Kantidakis, Georgios
    Litiere, Saskia
    Neven, Anouk
    Vinches, Marie
    Judson, Ian
    Schoeffski, Patrick
    Wardelmann, Eva
    Stacchiotti, Silvia
    D'Ambrosio, Lorenzo
    Marreaud, Sandrine
    van der Graaf, Winette T. A.
    Kasper, Bernd
    Fiocco, Marta
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2021, 154 : 253 - 268
  • [5] New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC- Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas
    Kantidakis, Georgios
    Litiere, Saskia
    Neven, Anouk
    Vinches, Marie
    Judson, Ian
    Blay, Jean-Yves
    Wardelmann, Eva
    Stacchiotti, Silvia
    D'Ambrosio, Lorenzo
    Marreaud, Sandrine
    van der Graaf, Winette T. A.
    Kasper, Bernd
    Fiocco, Marta
    Gelderblom, Hans
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : 261 - 276
  • [6] First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
    Young, R. J.
    Natukunda, A.
    Litiere, S.
    Woll, P. J.
    Wardelmann, E.
    van der Graaf, W. T. A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3178 - 3186
  • [7] Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
    Benson, C.
    Ray-Coquard, I.
    Sleijfer, S.
    Litiere, S.
    Blay, J. -Y.
    Le Cesne, A.
    Papai, Z.
    Judson, I.
    Schoffski, P.
    Chawla, S.
    Gil, T.
    Piperno-Neumann, S.
    Marreaud, S.
    Dewji, M. R.
    van der Graaf, W. T. A.
    GYNECOLOGIC ONCOLOGY, 2016, 142 (01) : 89 - 94
  • [8] Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas An exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)
    Sleijfer, Stefan
    Ouali, Monia
    van Glabbeke, Martine
    Krarup-Hansen, Anders
    Rodenhuis, Sjoerd
    Le Cesne, Axel
    Hogendoorn, Pancras C. W.
    Verweij, Jaap
    Blay, Jean-Yves
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (01) : 72 - 83